BioCardia (NASDAQ: BCDA) maps FDA path for Helix and cell therapies
Rhea-AI Filing Summary
BioCardia, Inc. (BCDA) reports that the FDA has confirmed and accepted the meeting minutes from its Pre-Submission Meeting for the Helix Transendocardial Delivery Catheter System, making those minutes final.
BioCardia plans to submit a follow-on pre-submission for Helix this quarter, incorporating FDA advice, which the company states could enable Helix approval via the De Novo pathway. Management believes that, if successful, independent Helix market clearance may support development and commercial partnering for investigational cell, gene, and protein therapeutics. The company also highlights a broader pipeline and lists anticipated catalysts, including CardiAMP and CardiALLO cell therapy milestones, Helix regulatory steps, and Heart3D fusion imaging first-in-man readiness.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Press release date: August 24, 2026
CardiAMP Japan PMDA submission: Q4 ’26
CardiAMP Japan approval target: Q4 ’27
+4 more
7 metrics
Press release date
August 24, 2026
Date of BioCardia’s announcement of FDA confirmation of Helix meeting minutes
CardiAMP Japan PMDA submission
Q4 ’26
Planned timing for CardiAMP Cell Therapy Japan PMDA submission for approval
CardiAMP Japan approval target
Q4 ’27
Listed anticipated timing for CardiAMP Cell Therapy approval in Japan
HF II enrollment completion
Q3 ’28
Anticipated timing for HF II study to complete enrollment
HF II topline data
Q3 ’29
Anticipated timing for HF II topline data readout
Helix FDA pre-sub amendment
Q3 ’26
Planned timing for Helix Delivery FDA pre-submission amendment
Heart3D first in man ready
Q1 ’27
Target readiness milestone for Heart3D fusion imaging platform
Key Terms
De Novo pathway, Pre-Submission Meeting, transendocardial, intramyocardially, +2 more
6 terms
De Novo pathway regulatory
"which could enable Helix approval via the De Novo pathway"
A de novo pathway is a regulatory route that allows manufacturers to win approval for a novel low- to moderate-risk medical device when there is no previously approved similar product, by showing reasonable assurance of safety and effectiveness. It matters to investors because successful de novo clearance opens a company to an untapped market and can create a first-mover advantage while reducing long-term regulatory uncertainty—like getting a permit to open a new type of store in a neighborhood where none existed before.
Pre-Submission Meeting regulatory
"receipt of FDA confirmation of the outcome of its Pre-Submission Meeting"
A pre-submission meeting is a planned discussion between a company and a regulatory agency to review plans and data before the company formally files for product approval. It matters to investors because the meeting can reveal what additional tests or information regulators will require, helping reduce surprise delays or costs—think of it like showing a building inspector your blueprints before applying for a construction permit to catch problems early.
transendocardial medical
"The Helix transendocardial delivery catheter is an enabling platform"
Transendocardial describes a method of delivering a drug, cell therapy, or device by passing through the heart’s inner lining (the endocardium) directly into the heart muscle. Investors should care because this targeted, catheter-based approach can improve effectiveness and reduce systemic side effects compared with general delivery, but it also brings procedural risks, specialized equipment needs, and specific regulatory and reimbursement considerations—like sending a repair crew straight through the engine housing rather than treating the whole car.
intramyocardially medical
"delivery of therapeutic and diagnostic agents to the heart intramyocardially"
Delivered or injected directly into the myocardium, the thick muscular wall of the heart. The term describes a route of administration for drugs, cells, devices, or surgical therapies where the treatment is placed inside the heart muscle rather than into a blood vessel or elsewhere. For investors, it signals a local, targeted approach that can affect clinical risks, delivery complexity, regulatory pathways, and potential costs—like fixing a problem by working on a single wall of a house instead of treating the whole building.
forward-looking statements regulatory
"This press release contains forward-looking statements that are subject"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
cell-derived therapeutics medical
"a global leader in cellular and cell-derived therapeutics for the treatment"
Therapies made from living cells that are grown, modified, or collected and then given to patients to treat or cure diseases, such as using immune or stem cells to replace damaged tissue or fight cancer. Investors care because these products can offer large clinical benefits and market returns but come with high development costs, complex manufacturing and strict regulatory hurdles—think of them like nurturing a high‑reward, high‑risk crop that must be carefully cultivated to succeed.
FAQ
What FDA update did BioCardia (BCDA) announce regarding the Helix catheter?
BioCardia announced that the FDA has reviewed and accepted the meeting minutes from its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System, making them final and confirming the understanding previously described by the company.
What are BioCardia’s next regulatory steps for Helix according to this 8-K?
BioCardia stated it intends to submit a follow-on pre-submission for Helix this quarter incorporating FDA advice, which it says could enable approval via the De Novo pathway if successful.
How could Helix market clearance impact BioCardia (BCDA)?
The company states that, if successful, an independent Helix market clearance should enhance development and commercial partnering for high value investigational cell, gene, and protein therapeutics that use the Helix delivery platform.
What upcoming CardiAMP cell therapy milestones does BioCardia list?
For CardiAMP Cell Therapy, BioCardia lists an anticipated Q4 ’26 peer‑reviewed manuscript, Q4 ’26 Japan PMDA submission for approval, Q4 ’27 Japan approval, Q3 ’28 HF II completes enrollment, and Q3 ’29 HF II topline data.
What other future catalysts does BioCardia (BCDA) highlight?
The company lists Q3 ’26 FDA pre-sub amendment for Helix Delivery and Q1 ’27 first in man ready for its Heart3D fusion imaging platform as additional upcoming catalysts.
What therapeutic areas does BioCardia focus on?
BioCardia describes itself as a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, with CardiAMP autologous and CardiALLO allogeneic cell therapies and multiple cardiac clinical-stage product candidates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
